Using the Morbidity and Mortality Conference Model to Explore and Improve Community-Based Oncology Care (Video Program)KEYNOTE-021 trial: Evaluating the addition of pembrolizumab to chemotherapy for advanced NSCLC
0:56 minutes.
TRANSCRIPTION:
DR WAKELEE: There have been several Phase I and II trials that have been looking at combining checkpoint inhibitors with chemotherapy. And so the pembrolizumab data was updated at ESMO. There’s also been work with atezolizumab. And in all of those trials, especially the platinum/pembro plus checkpoint inhibitor, the response rates have been like 70%, 60% to 70%, which has been quite striking. What we haven’t seen as much of is, what does that mean for overall survival? What does that mean for progression-free survival? And the data that’s out there is still smaller numbers. So I don't know that it’s truly practice-changing yet, but I’m really watching those trials with a lot of interest. |